Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewOlanzapine is an antagonist of 5-HT2A and dopamine D2 receptors (Ki values are 4 and 11 nM respectively). Also displays affinity for a range of other receptors including D1 and D4, 5-HT2C, α1, H1 and M1-4 receptors (Ki values range between 1.9 and 31 nM). Atypical antipsychotic. Displays anticholinergic properties. Also a highly potent activator of hM4Di DREADDs (EC50 values are 5 nM in vitro and 7 nM in vivo).
Olanzapine is also offered as part of the Tocriscreen 2.0 Max and Tocriscreen FDA-Approved Drugs. 了解 Tocris 化合物库的更多信息。
分子量 | 312.43 |
公式 | C17H20N4S |
储存 | Store at +4°C |
纯度 | ≥99% (HPLC) |
CAS Number | 132539-06-1 |
PubChem ID | 4585 |
InChI Key | WXPNDRBBWZMPQG-UHFFFAOYSA-N |
Smiles | CC4=CC2=C(S4)NC1=CC=CC=C1N=C2N3CCN(C)CC3 |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
溶剂 | 最高浓度 mg/mL | 最高浓度 mM | |
---|---|---|---|
溶解性 | |||
DMSO | 31.24 | 100 | |
1eq. HCl | 31.24 | 100 |
以下数据基于产品分子量 312.43。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
浓度/溶剂体积/质量 | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 3.2 mL | 16 mL | 32.01 mL |
5 mM | 0.64 mL | 3.2 mL | 6.4 mL |
10 mM | 0.32 mL | 1.6 mL | 3.2 mL |
50 mM | 0.06 mL | 0.32 mL | 0.64 mL |
参考文献是支持产品生物活性的出版物。
Tollefson and Taylor (2000) Olanzapine: preclinical and clinical profiles of a novel antipsychotic agent. CNS Drug Reviews 6 303
Moore et al (1992) The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent. J.Pharmacol.Exp.Ther. 262 545 PMID: 1354253
Bymaster et al (1996) Radioreceptor binding profile of the atypical antipsychotic olanz. Neuropsychopharmacology 14 87 PMID: 8822531
If you know of a relevant reference for Olanzapine, please let us know.
关键词: Olanzapine, Olanzapine supplier, 5ht2a, 5ht2c, serotonergics, dopamine, dopaminergics, d2, antagonists, atypical, antipsychotics, thienobenzodiazepine, chemogenetics, DREADD, D2, Receptors, DREADDs, 5-HT2A, 4349, Tocris Bioscience
引用文献是使用了 Tocris 产品的出版物。 Olanzapine 的部分引用包括:
Czysz et al (2015) Lateral diffusion of Gαs in the plasma membrane is decreased after chronic but not acute antidepressant treatment: role of lipid raft and non-raft membrane microdomains. Nat Methods 40 766 PMID: 25249058
Mitradas M et al (2020) Serotonin 2A (5-HT2A) receptor affects cell-matrix adhesion and the formation and maintenance of stress fibers in HEK293 cells. Sci Rep 10 21675 PMID: 33303826
Joshi and Panicker (2019) Identifying the In Vivo Cellular Correlates of Antipsychotic Drugs. Eneuro 5 PMID: 30713996
Pérez-Gómez et al (2018) A phenotypic Caenorhabditis elegans screen identifies a selective suppressor of antipsychotic-induced hyperphagia. Nat Commun 9 5272 PMID: 30532051
您是否知道使用了 Tocris Olanzapine 的优秀论文? 请告知我们.
目前没有该产品的评论。 Be the first to review Olanzapine and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。
Written by Nicholas M. Barnes and John F. Neumaier, this review summarizes the various serotonin receptor subtypes and their importance in mediating the role of serotonin in numerous physiological and pharmacological processes. Compounds available from Tocris are listed.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.